Skip to main navigation Skip to search Skip to main content

Long-term follow-up of lenalidomide in relapsed/ refractory mantle cell lymphoma: Subset analysis of the NHL-003 study

  • P. L. Zinzani
  • , J. M. Vose
  • , M. S. Czuczman
  • , C. B. Reeder
  • , C. Haioun
  • , J. Polikoff
  • , H. Tilly
  • , L. Zhang
  • , K. Prandi
  • , J. Li
  • , T. E. Witzig

Research output: Contribution to journal › Article › peer-review

Abstract

Background: Mantle cell lymphoma (MCL) is an uncommon type of non-Hodgkin lymphoma with poor overall prognosis, requiring the development of new therapies. Lenalidomide is an immunomodulatory agent demonstrating antitumor and antiproliferative effects in MCL. We report results from a long-term subset analysis of 57 patients with relapsed/refractory MCL from the NHL-003 phase II multicenter study of single-agent lenalidomide in patients with aggressive lymphoma Design: Lenalidomide was administered orally 25 mg daily on days 1-21 every 28 days until progressive disease (PD) or intolerability. The primary end point was overall response rate (ORR). Results: Fifty-seven patients with relapsed/refractory, advanced-stage MCL had a median of three prior therapies. The ORR was 35% [complete response (CR)/CR unconfirmed (CRu) 12%], with a median duration of response (DOR) of 16.3 months (not yet reached in patients with CR/CRu) by blinded independent central review. The median time to first response was 1.9 months. Median progression-free survival was 8.8 months, and overall survival had not yet been reached. The most common grade 3/4 adverse events (AEs) were neutropenia (46%), thrombocytopenia (30%), and anemia (13%). Conclusions: These results show the activity of lenalidomide in heavily pretreated, relapsed/refractory MCL. Responders had a durable response with manageable side-effects. Clinical trial number posted on www.clinicaltrials.gov NCT00413036.

Original languageEnglish (US)
Pages (from-to)2892-2897
Number of pages6
JournalAnnals of Oncology
Volume24
Issue number11
DOIs
StatePublished - Nov 2013

Keywords

  • Lenalidomide
  • Mantle cell lymphoma
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology

Fingerprint

Dive into the research topics of 'Long-term follow-up of lenalidomide in relapsed/ refractory mantle cell lymphoma: Subset analysis of the NHL-003 study'. Together they form a unique fingerprint.

Cite this